DUBLIN--(BUSINESS WIRE)--Opsona Therapeutics Ltd (‘Opsona’), the innate immune drug development company focused on novel therapeutic approaches to treat autoimmune, inflammatory diseases and oncology, today announced the issuances of US Patent 8,734,794 and European Patent, EP2,451,842, which cover the Opsona developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof.
TLR-2 plays an important role in the induction and progression of a number of non-pathogen associated inflammatory conditions including ischaemia reperfusion injury (delayed graft function in renal transplantation, myocardial infarct), certain cancer, autoimmune diseases, diabetes, Alzheimer’s disease and atherosclerosis.
Help employers find you! Check out all the jobs and post your resume.
